WithdrawnNot Applicable

A Non-randomised, Non-inferiority Comparative Study of Oral Actiskenan (Morphine Sulfate) Versus Intranasal Sufentanil in the Early Management of Severe Acute Pain in Emergency Departments.

Stopped: Study not carried out

France0Started 2026-01-31

Plain-language summary

The main objective of this study is to evaluate whether the analgesic protocol combining oral Actiskenan is non-inferior to the protocol combining intranasal Sufentanil for treating severe pain in patients admitted to the emergency department. The primary endpoint will be the difference between the numerical pain rating scale score at the initial assessment performed by the triage nurse (baseline) and the numerical pain rating scale score measured 30 minutes after treatment administration.

Who can participate

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Patient presenting with severe acute pain of medical or traumatic origin at admission, with a score of 6 or higher on the numerical pain rating scale; * Aged 18 years or older; * No prior use of WHO step III analgesic before admission; * Hemodynamic, respiratory, and neurological stability; * Patient informed about the study and not opposed to participation. Non-Inclusion Criteria: * Pain related to exacerbation of chronic and/or neuropathic pain; * Sickle cell crisis; * Patient with substance abuse.

What they're measuring

Numerical Pain rating scale score 30 minutes after analgesic treatment is given

Timeframe: 30 minutes after analgesic treatment is given

Trial details

NCT IDNCT07344350

SponsorGroupe Hospitalier de la Region de Mulhouse et Sud Alsace

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2026-05-01

View on ClinicalTrials.gov More Severe Acute Pain trials